Table 2.
Clinical Characteristics of Stage IV LCNEC Patients with or without Immunotherapy: Propensity Score Matched Cases
| Immunotherapy | Total | P value | ||
|---|---|---|---|---|
| Yes | No | |||
| Total | 37 (100%) | 37 (100%) | 74 (100%) | |
| Age | ||||
| <70 | 25 (68%) | 26 (70%) | 51 (69%) | 0.8017 |
| 70+ | 12 (32%) | 11 (30%) | 23 (11%) | |
| Sex | ||||
| Male | 23 (62%) | 25 (68%) | 48 (65%) | 0.6263 |
| Female | 14 (38%) | 12 (32%) | 26 (35%) | |
| Race | ||||
| Whites and Others | 37 (100%) | 37 (100%) | 74 (100%) | 0.7438 |
| Insurance status | ||||
| Uninsured | 0 (0%) | 0 (0%) | 0 (0%) | 1 |
| Others | 37 (100%) | 37 (100%) | 74 (100%) | |
| Institution | ||||
| Academic | 17 (46%) | 16 (43%) | 33 (45%) | 0.8151 |
| Others | 20 (54%) | 21 (57%) | 41 (55%) | |
| Charlson-Deyo score | ||||
| 0-1 and 2-3+ | 37 (100%) | 37 (100%) | 74 (100%) | 0.1647 |
| Brain metastasis | ||||
| Yes and No | 37 (100%) | 37 (100%) | 74 (100%) | 0.2785 |
| Liver metastasis | ||||
| Yes | 10 (27%) | 11 (30%) | 21 (28%) | 0.7965 |
| No | 27 (73%) | 26 (70%) | 53 (72%) | |
| Surgery for primary lesion | ||||
| Yes and No | 37 (100%) | 37 (100%) | 74 (100%) | 0.3039 |
| Radiation | ||||
| Yes | 17 (46%) | 16 (43%) | 33 (45%) | 0.8151 |
| No | 20 (54%) | 21 (57%) | 41 (55%) | |
| Chemotherapy | ||||
| Yes and No | 37 (100%) | 37 (100%) | 74 (100%) | 0.6433 |
Note: Due to NCDB agreement, cells with less than 10 cases in Race, Charlson-Deyo score, Brain metastasis and Chemotherapy were combined with other opposing cells